# Harmony Baby Nutrition

Baby formula made out of human milk molecules

- Canonical URL: https://wefunder.com/harmony.baby.nutrition
- Entity ID: wefunder:company:181747
- Last updated: 2026-06-07T23:54:19Z
- Generated at: 2026-06-08T03:01:33Z

## Quick facts
- $7.5M raised from top-tier VCs including SOSV, Safar Partners, Rethink, & MassVentures
- Repeat founder & CEO who previously built the #2 fastest growing SME in Brazil
- 4 patents filed and 55+ prototypes developed to mirror human milk form and function
- Supported by Pediatric Allergy and Immunology experts from Harvard, URMC, BCM, UC Davis, and more
- Partnered with the Former President of Gerber (subsidiary of Nestle)
- First product for toddlers launching 2026
- Disrupting the $100B+ global pediatric formula market

## Active fundraises
- wefunder:fundraise:141961: 4(a)(6) successful (USD)
- wefunder:fundraise:141960: 4(a)(6) open (USD)

## Story
Harmony Baby Nutrition is building next generation pediatric formulas, offering the closest match to human milk, ever by using human milk components.Led by a repeat founder in the infant nutrition space and supported by world-renowned pediatric and regulatory experts from Harvard, Mass General, Pfizer, Gerber, and Nestlé, Harmony is creating a superior alternative in a $100B+ market ripe for disruption.With $13.5M raised from top VCs and grants, we’ve completed rigorous R&D and are now entering the market with our first product, an allergy-friendly toddler formula. We will then expand to a broader range of revolutionary infant formula products all built on the same clean-label, human milk foundation.At Harmony, we believe the 130M+ infants and toddlers worldwide who rely on formula shouldn’t have to compromise. By redesigning formula around human milk components, we’re creating products that parents, babies, and physicians love – because they are designed to closely replicate the form and function of human milk, while tasting great - giving the next generation the best possible start in life.Infant formula was invented more than 100 years ago, yet its evolution has been minimal, limited to incremental changes and the addition of a few new ingredients.Most formulas still rely on cow’s milk as the core ingredient, whose proteins were never intended for the human immune or digestive system. While these products provide calories and the basic nutrition, they lack the bioactive components essential for gut development and immune programming.Decades of research has proven that human milk is far more complex and serves many purposes that cow’s milk alone will never meet.Formula is a critical life line for millions of infants. By six months old, about 90% of babies in the U.S. rely on formulas when human milk is not available. Globally, more than 50% of infants consume formula at some stage.Yet 1 in 5 babies cannot tolerate standard formula made with cow’s milk. They suffer from inflammation, digestive distress, and stressful feeding cycles during the most critical months of development.When standard formulas fail, parents turn to hypoallergenic options that strip out allergenic proteins. What’s left is often formulas that smell awful, taste bitter and are packed with industrially added sugars - leading many babies to reject them.For many families, feeding becomes a daily fight. Parents persist because they have no other choice.Until now, no formula addresses both the nutrition gap and the function gap between formula and human milk.Enter Harmony. We’re transforming the $100B+ global infant nutrition market by designing formulas that mirror human milk in both form and function.Harmony is at the forefront of cutting-edge formulation science.We source best-in-class, human-milk-inspired components, key human milk oligosaccharides (HMOs), and essential fatty acids found in breast milk.We then apply deep formulation science and product development expertise to assemble them into infant nutrition that is stable, safe, effective and enjoyable.We use lactose as the primary carbohydrate because it’s actually the main ingredient in human milk. Babies are actually really good at digesting lactose. Lactose intolerance, a rare disease, does not develop until adulthood.Instead of removing allergens from cow’s milk, breaking down components further and further, Harmony designs an entirely new formulation matrix built around human milk–like components and how they behave together in a real product.That’s what allows our formulas to be both hypoallergenic and drinkable - a combination the category has struggled to achieve for decades.Harmony is scaling an infant nutrition platform, not a single product. Our patented technology enables a clear product pipeline: we enter through a high-need, high-margin hypoallergenic (HA) market, then expand into the broader routine infant nutrition category. Each product builds on the same core, human-milk-inspired foundation, allowing us to scale efficiently from niche to mass market.The first generation of products we’re bringing to market, our allergy-friendly toddler formula Melodi, is launching in 2026.We’re beginning with toddler nutrition in an underserved category because of the lower barriers to entry. This early product will also allow us to validate our approach and build trust with parents and healthcare providers.Melodi benefits from FDA clearance because we are using approved ingredients and targeting toddlers. Our next step will be to show safety for babies 0 to 12 months via a clinical trial.From this foundation, we will then expand into the broader infant market with bioactive, human-milk inspired compositions, all built on the same formulation platform.Our pipeline includes extensively hydrolysed formulas and amino acid formulas, and a roadmap to launch several revolutionary infant formula products, all built on the same clean-label, taste-forward, human milk–inspired foundation.With Harmony, parents don’t need to cycle through multiple formulas when human milk is not available. Our suite of products are designed to work from birth, reducing feeding uncertainty for all babies during the most critical months of life.Harmony is developed in partnership with the experts who shape infant nutrition. We collaborate with leaders in pediatric allergy, immunology, and nutrition from Harvard/Massachusetts General Hospital, UC Davis, Baylor College of Medicine, and the University of Rochester.Clinicians are seeing rising rates of infant allergies with few nutritional options that balance tolerance and development. 50% of pediatricians we spoke with said they prefer Harmony’s new concept over well known brands.Harmony gives pediatricians a credible alternative they can confidently recommend.Melodi was designed to improve acceptance and to lead the sustained use during key developmental months.Harmony is led by a repeat founder with over 20 years of experience in infant nutrition, having launched more than 30 science-backed products and supported thousands of babies with dietary restrictions.Our team brings deep operating experience alongside former Nestlé and Gerber regulatory and manufacturing leaders and world-renowned pediatric allergy and nutrition experts from leading medical institutions like Massachusetts General and Harvard Medical.Together, we bring a rare combination of scientific depth and proven execution required to build a global category-defining infant nutrition company.Infant nutrition is a $100B+ global market driven by essential and recurring consumption. In the U.S., more than 90% of babies consume formula by six months, either exclusively or as a supplement.Within this market, hypoallergenic formula represents one of the most critical segments, serving up to 17% of infants that experience acute food allergy symptoms such as Food Protein-Induced Allergic Proctocolitis (FPIAP). It is a high-urgency category driven by medical necessity, where increasing pediatric awareness and earlier diagnosis are pushing families into hypoallergenic formulas sooner and for longer periods of time. The result is a fast-growing segment where parents are actively seeking better solutions.Harmony is also creating an entirely new category in this market: functional formula.Harmony operates in a sticky, repeat-purchase category where brand loyalty is high. With hypoallergenic formulas in particular, once tolerance is established, parents rarely switch products.Usage is daily, predictable, and often medically guided, resulting in strong retention, high lifetime value, and meaningful switching costs.Early data supports the strength of our model. Customers purchase at a premium price point of approximately $50 per can, consume at expected clinical volumes, and remain on product for multiple months, generating more than $2,400 in lifetime value per customer.These unit economics apply to the entire suite of our product roadmap, from the hypoallergenic toddler product to bioactive baby formulas.We’re projecting over $7M in sales purely from our Gen 1 products by 2029. However the full enterprise value of Harmony at that point will be much greater as we get closer to bringing our Gen 2 and Gen 3 products to market in late 2029 and 2030.The pharmaceutical-grade innovative nature of these later stage products serves as both a competitive moat and significant value driver as we reach key clinical and regulatory milestones and accumulate more IP.Infant and medical nutrition is one of the most proven exit categories in consumer health, with multiple multi-billion-dollar acquisitions by global leaders like Nestlé, Danone, and Reckitt. These outcomes demonstrate sustained M&A appetite for differentiated infant and pediatric nutrition assets at scale.With patented, human-milk-inspired technology, a scalable product platform, and entry through a high-need hypoallergenic segment, Harmony Baby Nutrition has multiple potential exit paths, including strategic acquisition by global infant nutrition or medical nutrition leaders as the platform expands.Harmony Baby Nutrition is leading the next generation of infant nutrition in a massive $100B+ market - bringing biotechnology to the baby aisle to help the next generation thrive, not just survive.We’re raising on Wefunder to give parents, clinicians, and mission-aligned investors the opportunity to own a stake in a company redefining baby formula, alongside top-tier backers including SOSV, Safar Partners, Rethink, and MassVentures.Your investment will help us scale production and showcase how science development can change the game in infant nutrition.Together, we can give millions of babies and toddlers clean nutrition as close to human milk as possible.Join us in reshaping the future of pediatric nutrition.wefunder.com/harmonybabynutrition

## FAQ
1. **Hello, congrats on your success to date and great problem you are trying to solve. Business question - when do you expect sales to start?**
   - Hi @Freeman, Great to hear from you! Manufacturing starts next month, and we’re on track to launch sales by the end of Q1 2026.This fundraising round is dedicated to securing manufacturing costs and accelerating commercial efforts, including strategic team expansion. We’re fully committed to executing this plan and confident in the milestones ahead.
2. **Hi Wendel, First Of All Happy New and wishing all the Best at Harmony. I am trying to contact you to support on all nutrients Supply. How can I contact you directly? Thanks and Kind Regards. Leon Reis**
   - Hi Leon, you can contact care@harmonybabynutrition.com
3. **Team, 1). Are there any additional regulatory approvals you expect to require in the future? 2). Given that you already have several venture capital firms on your cap table and recently received a grant, why pursue a community round instead of raising capital from existing inv...**
   - Hi Kunal, great to hear from you! Please find my answers below: 1. We have a full pipeline of infant nutrition products. Our Generation 1 products are already cleared and on their way to market. Products in Generations 2 and 3, which include a full complement of human milk components, will require additional regulatory steps and approvals before launch. Please keep in mind that Gen 1 products serve as the key foundation for building the most sophisticated and humanized infant nutrition soluti...
4. **Hi, I'm Sherwood Neiss, Managing Partner at D3VC (d3vc.ai). We are an early-stage venture fund that invests in select Regulation Crowdfunding offerings. Yours scored high in our algorithm, and we had a chance to review it during a recent investment committee meeting. Our team ...**
   - Hi Sherwood, Thank you for your excellent questions. They show real depth of understanding and touch on the core elements of the Harmony opportunity, especially the transformation of a $100B industry that hasn’t meaningfully changed in 100 years. We truly appreciate it. Our answers below: 1. Industry Safety Concerns Harmony team brings more than two decades of experience in the industry and implements a conservative, approach to supply chain safety and ingredient sourcing, very similar to a p...
5. **amazing! I invested in several companies centered around babies, therefore, this is very intriguing. I am a vc and invest on sites like this. you are very smart to open a community round. congrats on what you have accomplished so far. few questions 1. with that being said I no...**
   - Hi John Great to hear from you! Thank you for your support! Please find the answers below: 1. Ambassador program We are developing an Advocacy Ecosystem targeting 'Allergy-Influencer' parents and community leaders. Harmony’s technical differentiation defined by a nutritional profile mirroring human milk, superior palatability, and a clean label provides a powerful, science-backed narrative for digital communicators seeking to solve the 'allergy gap' for their audiences.” Additionally, our hea...

## Team
- Wendel Afonso (Founder and CEO)
- Shirley Szeto (Head of Business Strategy and Operations)
- Mariana Souza (VP, Formulation)
- Mauro Ramalho Silva (VP, Quality and Manufacturing)
- Dr. Robert DiGregorio, D.O.  (Senior Regulatory Advisor)
- Dr. Victoria Mackenzie Martin, MD (Senior Medical Advisor )

## Q&A
- Q: Hi, I'm Sherwood Neiss, Managing Partner at D3VC (d3vc.ai). We are an early-stage venture fund that invests in select Regulation Crowdfunding offerings. Yours scored high in our algorithm, and we had a chance to review it during a recent investment committee meeting. Our team has the following follow-up questions we were hoping you could answer for us: 1. Industry Safety Concerns We've been following the recent infant formula contamination issues affecting Nestlé, Danone, and ByHeart — including recalls across 60+ countries, hospitalizations, and unfortunately some infant deaths tied to contaminated ingredients like ARA oil and botulism spores. While Harmony isn't named in these incidents, the broader industry is clearly facing scrutiny around supply chain complexity and ingredient sourcing as formulas become more nutritionally sophisticated. How is Harmony approaching supply chain safety and ingredient sourcing for Melodi and your future Gen 2 products? What quality control and testing protocols do you have in place, particularly for bioactive compounds? Does the precision fermentation approach for Gen 2 reduce or increase supply chain risk compared to traditional ingredient sourcing? 2. Market Differentiation The hypoallergenic formula market is large, but established players (Abbott, Nestlé, Danone) already offer specialized products. What is truly unique about Harmony's formulas relative to existing hypoallergenic products on the market? Is the primary advantage taste, digestibility, allergen profile, biological similarity to human milk, or something else? For Melodi (toddler formula) specifically, what is its clear competitive edge? 3. Regulatory Path & Cash Runway Your Gen 2 precision fermentation-based formulas will presumably require lengthy regulatory approval processes. What is your expected regulatory timeline in Brazil vs. the US for Gen 2? Will cash generated from Melodi sales be sufficient to bridge you to Gen 2 approvals, or will additional fundraising be required? How does launching in Brazil first shape your go-to-market strategy for the US and Europe? 4. Geopolitical & Operational Risk With R&D operations and government funding based in Brazil: How do tariffs, trade regulations, and supply chain constraints affect your manufacturing costs? What are the logistics and regulatory hurdles for exporting to major markets like the US and Europe? Does the $5.9M Brazilian government grant come with any restrictions on where you can manufacture or sell? Thank you for your time. We look forward to your responses. — Sherwood Neiss, Managing Partner, D3VC
  - A: Hi Sherwood, Thank you for your excellent questions. They show real depth of understanding and touch on the core elements of the Harmony opportunity, especially the transformation of a $100B industry that hasn’t meaningfully changed in 100 years. We truly appreciate it. Our answers below: 1. Industry Safety Concerns Harmony team brings more than two decades of experience in the industry and implements a conservative, approach to supply chain safety and ingredient sourcing, very similar to a pharmaceutical‑grade quality systems. We operate using small-batch production rather than mass-scale manufacturing, which allows for tighter lot-level traceability, faster detection of deviations, and a significantly lower risk radius in the unlikely event of a quality issue. All manufacturing partners were selected for experience in specialty nutrition and regulated products and are subject to independent third-party audits and ongoing quality reviews, not one-time certifications. Our quality control framework spans incoming raw material verification, in-process controls, and finished-product testing, with particular rigor applied to bioactive compounds where purity and consistency are critical. For Gen 2 products, precision fermentation is a risk-reduction strategy rather than a risk amplifier: the technology is already widely used in biologics and pharmaceutical manufacturing, operates under more stringent quality standards than conventional food supply chains, and produces highly defined ingredients in controlled, reproducible environments. Note: Gen 3 product technology is designed to eliminate the primary types of microbial contamination recently observed in the infant nutrition industry, the highest number of infant formula contamination incidents ever recorded. Because Gen 3 products are manufactured as sterile, liquid formulations, similar to human milk, they remain free from microbial contamination throughout production. In addition, Gen 3 formulas can serve both healthy infants and those with allergies, something impossible for traditional cow’s‑milk‑based products. This is the most significant breakthrough the industry has seen in the last 100 years. 2. Market Differentiation: While it is true that incumbent players like Abbott, Nestlé, and Danone dominate the hypoallergenic formula market, the category is driven more by lack of alternatives than by parent satisfaction. Across online reviews, lead-generation campaigns, and direct conversations with parents at allergy and pediatric conferences, we consistently hear that families use existing products because they have no other viable options. Harmony’s differentiation lies in rethinking hypoallergenic nutrition beyond “clinical and technical compliance” toward biological similarity and usability. For Melodi, the competitive edge is the combination of a hypoallergenic profile with significantly improved taste and human milk similar composition, which becomes especially critical at the toddler stage. Unlike infants, toddlers have already developed taste preferences through solid foods, and refusal rates for traditional hypoallergenic formulas increase sharply at this age due to bitterness and poor palatability. Melodi is designed to address this exact gap by delivering allergy-free nutrition and reducing feeding stress for families during the developmentally period of a sensitive child. 3. Regulatory Path & Cash Runway For Gen 2, we are taking a regulatory-first approach in strategic geographies to showcase our innovations. Our regulatory team has identified Food Standards Australia New Zealand (FSANZ) and the Singapore Food Agency (SFA) as the fastest and most predictable pathways for precision-fermentation–derived ingredients, and we are planning Gen 2 go-to-market in 2029 following those approvals. For both US and Brazil Gen 2 approval is expected by 2030. While Melodi provides solid commercial validation, brand reputation, and operational cash flow, we do not expect Melodi sales alone to be sufficient to bridge us through Gen 2, as Gen 2 will require clinical trials to got to market; this phase will be supported by a Series A raise. Brazil plays a distinct and strategic role in our roadmap: because infant formula registration in Brazil does not require clinical trials under ANVISA, we plan to launch an infant formula there (Gen 1 products) ahead of the US, allowing us to build real-world usage data, manufacturing scale, and brand credibility with parents and pediatric stakeholders. This Brazil-first infant strategy is designed to de-risk and strengthen our eventual US infant launch narrative, while Europe is not a near-term priority unless pursued through a strategic partnership with an established regional player. 4. Geopolitical & Operational Risk Harmony’s exposure to geopolitical and operational risk is mitigated by both industry economics and our current operating structure. Infant and toddler formula is generally a healthy-margin category, which gives us room to absorb tariffs, duties, and incremental trade-related costs without materially impairing unit economics. Today, our primary manufacturing partner is based in Europe, and does not have have significant regulatory or logistical barriers importing finished product into the US, as infant and toddler formulas follow clear customs, labeling, and FDA notification pathways. While Brazil is a core R&D hub (1/5 of the US R&D costs), this does not materially constrain our global supply chain: the Brazilian government grant is designated for local R&D activities and the development of domestic manufacturing capability (Infant Formula Boutique manufacturing plant for high value products). This grant must be deployed locally, and does not support commercial execution. The government grant does not impose restrictions on where products can ultimately be sold and exportation is one of the key topics of support of the local government.
  - A: Hi Sherwood, Thank you for your excellent questions. They show real depth of understanding and touch on the core elements of the Harmony opportunity, especially the transformation of a $100B industry that hasn’t meaningfully changed in 100 years. We truly appreciate it. Our answers below: 1. Industry Safety Concerns Harmony team brings more than two decades of experience in the industry and implements a conservative, approach to supply chain safety and ingredient sourcing, very similar to a pharmaceutical‑grade quality systems. We operate using small-batch production rather than mass-scale manufacturing, which allows for tighter lot-level traceability, faster detection of deviations, and a significantly lower risk radius in the unlikely event of a quality issue. All manufacturing partners were selected for experience in specialty nutrition and regulated products and are subject to independent third-party audits and ongoing quality reviews, not one-time certifications. Our quality control framework spans incoming raw material verification, in-process controls, and finished-product testing, with particular rigor applied to bioactive compounds where purity and consistency are critical. For Gen 2 products, precision fermentation is a risk-reduction strategy rather than a risk amplifier: the technology is already widely used in biologics and pharmaceutical manufacturing, operates under more stringent quality standards than conventional food supply chains, and produces highly defined ingredients in controlled, reproducible environments. Note: Gen 3 product technology is designed to eliminate the primary types of microbial contamination recently observed in the infant nutrition industry, the highest number of infant formula contamination incidents ever recorded. Because Gen 3 products are manufactured as sterile, liquid formulations, similar to human milk, they remain free from microbial contamination throughout production. In addition, Gen 3 formulas can serve both healthy infants and those with allergies, something impossible for traditional cow’s‑milk‑based products. This is the most significant breakthrough the industry has seen in the last 100 years. 2. Market Differentiation: While it is true that incumbent players like Abbott, Nestlé, and Danone dominate the hypoallergenic formula market, the category is driven more by lack of alternatives than by parent satisfaction. Across online reviews, lead-generation campaigns, and direct conversations with parents at allergy and pediatric conferences, we consistently hear that families use existing products because they have no other viable options. Harmony’s differentiation lies in rethinking hypoallergenic nutrition beyond “clinical and technical compliance” toward biological similarity and usability. For Melodi, the competitive edge is the combination of a hypoallergenic profile with significantly improved taste and human milk similar composition, which becomes especially critical at the toddler stage. Unlike infants, toddlers have already developed taste preferences through solid foods, and refusal rates for traditional hypoallergenic formulas increase sharply at this age due to bitterness and poor palatability. Melodi is designed to address this exact gap by delivering allergy-free nutrition and reducing feeding stress for families during the developmentally period of a sensitive child. 3. Regulatory Path & Cash Runway For Gen 2, we are taking a regulatory-first approach in strategic geographies to showcase our innovations. Our regulatory team has identified Food Standards Australia New Zealand (FSANZ) and the Singapore Food Agency (SFA) as the fastest and most predictable pathways for precision-fermentation–derived ingredients, and we are planning Gen 2 go-to-market in 2029 following those approvals. For both US and Brazil Gen 2 approval is expected by 2030. While Melodi provides solid commercial validation, brand reputation, and operational cash flow, we do not expect Melodi sales alone to be sufficient to bridge us through Gen 2, as Gen 2 will require clinical trials to got to market; this phase will be supported by a Series A raise. Brazil plays a distinct and strategic role in our roadmap: because infant formula registration in Brazil does not require clinical trials under ANVISA, we plan to launch an infant formula there (Gen 1 products) ahead of the US, allowing us to build real-world usage data, manufacturing scale, and brand credibility with parents and pediatric stakeholders. This Brazil-first infant strategy is designed to de-risk and strengthen our eventual US infant launch narrative, while Europe is not a near-term priority unless pursued through a strategic partnership with an established regional player. 4. Geopolitical & Operational Risk Harmony’s exposure to geopolitical and operational risk is mitigated by both industry economics and our current operating structure. Infant and toddler formula is generally a healthy-margin category, which gives us room to absorb tariffs, duties, and incremental trade-related costs without materially impairing unit economics. Today, our primary manufacturing partner is based in Europe, and does not have have significant regulatory or logistical barriers importing finished product into the US, as infant and toddler formulas follow clear customs, labeling, and FDA notification pathways. While Brazil is a core R&D hub (1/5 of the US R&D costs), this does not materially constrain our global supply chain: the Brazilian government grant is designated for local R&D activities and the development of domestic manufacturing capability (Infant Formula Boutique manufacturing plant for high value products). This grant must be deployed locally, and does not support commercial execution. The government grant does not impose restrictions on where products can ultimately be sold and exportation is one of the key topics of support of the local government.
- Q: There is a product on the market called Kepos, a human milk biosimilar. How is your product fundamentally different from Kepos and what would prevent a company like Kepos from pursuing litigation against your company since they, too, have no doubt secured patents? Here is some information on Kepos: Patent and Intellectual Property Status Patents in Progress: As of late 2025, the company has multiple patents in the works specifically focused on novel synbiotic delivery systems Velocity Catalyst Funds. Proprietary Blends: Their flagship product uses a proprietary blend of human milk oligosaccharides (HMOs) and human milk lactoferrin (hmLF). Kēpos Research Partnership: The company was incubated and partnered with the University of Chicago, where it utilizes advanced purity testing like proteomics and metabolomics to validate its bio-identical compounds Kēpos Shop. Product Technology Precision Fermentation: Kēpos does not extract its nutrients from actual breast milk; instead, it uses precision fermentation to create compounds that are chemically identical to those found in human milk. In view of the above information, what would prevent other companies, including the biggest players in baby food, from engineering eerily similar products to yours, differentiating them just enough to secure a separate patent (such as Kepos apparently is) and marketing them internationally? Another company named Prolacta Biocience Inc, appears to be targeting the same market as Harmony with similar objectives. Here is some information on Prolacta Bioscience Inc: Prolacta Bioscience produces 100% human milk-based nutritional products for premature and critically ill infants. Their portfolio is protected by an extensive patent library covering processing methods, testing, and specific milk compositions. Key Products: Prolacta's products are primarily used in Neonatal Intensive Care Units (NICUs).Prolact+ H2MF®: A line of human milk-based fortifiers (e.g., Prolact+4, Prolact+6, Prolact+8) intended to be added to donor or mother's milk to increase caloric and nutrient density.Prolact RTF™: The first ready-to-feed human milk-based premature infant formula (e.g., Prolact RTF 24, Prolact RTF 28). Prolact CR®: A human milk caloric fortifier (fat modular) used to provide concentrated calories. Surgifort®: A fortifier recently approved for term infants recovering from gastroschisis surgery. PreemieFort®: The prescription drug brand name used for their products in Japan. Notable Patents: The company holds numerous patents related to the safety and optimization of human milk products. You can view a comprehensive list of patents assigned to Prolacta Bioscience on Justia. Human Milk Compositions: US8545920B2 covers specific human milk compositions and methods for making them, according to Google Patents. Milk Testing: US8278046B2 details methods for testing milk for adulteration or biological markers. High Fat Products: ES3015561T3 focuses on the development of high-fat human milk products like Prolact CR. Bioactive Retention: The company uses a patented manufacturing process designed to retain the essential bioactive components of human milk. Subsequently, it would seem like the market is already quickly becoming saturated with similar or like products, and that these companies are already ahead of yours, currently marketing and selling products as established entities? Your response? UPDATE: As of May 18 (1 week, no response). The silence is deafening.
  - A: Hi Jared, I just realized that I responded to you on the wrong thread on May 11 (see below). My apologies for any confusion. Please let me know if you have any additional questions. I’d also be happy to jump on a call and to walk you through the work we’re doing and address anything further. Best regards, Del calendly.com/harmonybabynutrition/30minAnswer below:Hi Jared, great to hear from you, and thank you for the thoughtful questions. There are significant differences between Harmony and the two companies you referenced, Kepos and Prolacta. Both operate in distinct segments , NICU-focused medical nutrition sourced from donor human milk and adult fermentation-based supplements, respectively, while Harmony is building an entirely new category within infant nutrition.Harmony’s core differentiation lies in its use of real human milk–derived ingredients produce vai precision fermentation, combined and formulated for healthy, full‑term infants and families outside the hospital setting, with a consumer‑facing brand and regulatory strategy aligned to infant nutrition rather than adult nutrition or prescription medical foods. This materially reduces any litigation risk because Harmony’s inputs, processing methods, product intent, and regulatory classification differ from Kepos’ supplement fermented‑based synbiotic IP and Prolacta’s hospital‑centric fortifiers and NICU formulations. Patent law protects specific methods and compositions, not the broad concept of using human milk components, and Harmony operates in a distinct technical and commercial lane. We have also done an extensive Freedom to Operate analysis (FTO) prior to initiating the business with support of a top IP lawyer in the space.Furthermore, Harmony is difficult for competitors to copy because its protection goes beyond a single formula and instead relies on a broad family of composition-of-matter patents covering both hypoallergenic formulas (Gen 1 & 2) and routine formulas for allergic and healthy babies (Gen 3). These patents are designed to protect the specific use and combination of key human milk components, including lactose, HMOs, and human milk proteins , across ingredient ranges allowed by global regulators, creating strong and defensible barriers to entry. The portfolio also protects unique functional benefits that are not available in traditional cow’s-milk-derived formulas, such as allergy prevention and treatment mechanisms, single-SKU applicability for both allergic and healthy infants, and modular age-based customization that mirrors the natural progression of human milk. As a result, competitors attempting to launch similar products using comparable biological active components to mimic breast milk functions could infringe on Harmony’s patented composition and technology platform.
  - A: Hi Jared, I just realized that I responded to you on the wrong thread on May 11 (see below). My apologies for any confusion. Please let me know if you have any additional questions. I’d also be happy to jump on a call and to walk you through the work we’re doing and address anything further. Best regards, Del calendly.com/harmonybabynutrition/30minAnswer below:Hi Jared, great to hear from you, and thank you for the thoughtful questions. There are significant differences between Harmony and the two companies you referenced, Kepos and Prolacta. Both operate in distinct segments , NICU-focused medical nutrition sourced from donor human milk and adult fermentation-based supplements, respectively, while Harmony is building an entirely new category within infant nutrition.Harmony’s core differentiation lies in its use of real human milk–derived ingredients produce vai precision fermentation, combined and formulated for healthy, full‑term infants and families outside the hospital setting, with a consumer‑facing brand and regulatory strategy aligned to infant nutrition rather than adult nutrition or prescription medical foods. This materially reduces any litigation risk because Harmony’s inputs, processing methods, product intent, and regulatory classification differ from Kepos’ supplement fermented‑based synbiotic IP and Prolacta’s hospital‑centric fortifiers and NICU formulations. Patent law protects specific methods and compositions, not the broad concept of using human milk components, and Harmony operates in a distinct technical and commercial lane. We have also done an extensive Freedom to Operate analysis (FTO) prior to initiating the business with support of a top IP lawyer in the space.Furthermore, Harmony is difficult for competitors to copy because its protection goes beyond a single formula and instead relies on a broad family of composition-of-matter patents covering both hypoallergenic formulas (Gen 1 & 2) and routine formulas for allergic and healthy babies (Gen 3). These patents are designed to protect the specific use and combination of key human milk components, including lactose, HMOs, and human milk proteins , across ingredient ranges allowed by global regulators, creating strong and defensible barriers to entry. The portfolio also protects unique functional benefits that are not available in traditional cow’s-milk-derived formulas, such as allergy prevention and treatment mechanisms, single-SKU applicability for both allergic and healthy infants, and modular age-based customization that mirrors the natural progression of human milk. As a result, competitors attempting to launch similar products using comparable biological active components to mimic breast milk functions could infringe on Harmony’s patented composition and technology platform.
- Q: I think dopple on here will be a great partnership for you.
- Q: Hi Jared, great to hear from you, and thank you for the thoughtful questions. There are significant differences between Harmony and the two companies you referenced, Kepos and Prolacta. Both operate in distinct segments , NICU-focused medical nutrition sourced from donor human milk and adult fermentation-based supplements, respectively, while Harmony is building an entirely new category within infant nutrition. Harmony’s core differentiation lies in its use of real human milk–derived ingredients produce vai precision fermentation, combined and formulated for healthy, full‑term infants and families outside the hospital setting, with a consumer‑facing brand and regulatory strategy aligned to infant nutrition rather than adult nutrition or prescription medical foods. This materially reduces any litigation risk because Harmony’s inputs, processing methods, product intent, and regulatory classification differ from Kepos’ supplement fermented‑based synbiotic IP and Prolacta’s hospital‑centric fortifiers and NICU formulations. Patent law protects specific methods and compositions, not the broad concept of using human milk components, and Harmony operates in a distinct technical and commercial lane. We have also done an extensive Freedom to Operate analysis (FTO) prior to initiating the business with support of a top IP lawyer in the space.Furthermore, Harmony is difficult for competitors to copy because its protection goes beyond a single formula and instead relies on a broad family of composition-of-matter patents covering both hypoallergenic formulas (Gen 1 & 2) and routine formulas for allergic and healthy babies (Gen 3). These patents are designed to protect the specific use and combination of key human milk components, including lactose, HMOs, and human milk proteins , across ingredient ranges allowed by global regulators, creating strong and defensible barriers to entry. The portfolio also protects unique functional benefits that are not available in traditional cow’s-milk-derived formulas, such as allergy prevention and treatment mechanisms, single-SKU applicability for both allergic and healthy infants, and modular age-based customization that mirrors the natural progression of human milk. As a result, competitors attempting to launch similar products using comparable biological active components to mimic breast milk functions could infringe on Harmony’s patented composition and technology platform.
- Q: Quick question: are you currently leveraging any structured outreach (email lists or press distribution) to drive external traffic into the campaign? The reason I ask is because campaigns like yours tend to under perform not due to product quality, but due to limited exposure beyond platform discovery. I’ve worked on similar projects where we introduced a targeted email + press release system, bringing in highly relevant backers within a short window.
- Q: Hi, I'm Sherwood Neiss, Managing Partner at D3VC (d3vc.ai). We are an early-stage venture fund that invests in select Regulation Crowdfunding offerings. Yours scored high in our algorithm, and we had a chance to review it during a recent investment committee meeting. Our team has the following follow-up questions we were hoping you could answer for us: 1. Industry Safety Concerns We've been following the recent infant formula contamination issues affecting Nestlé, Danone, and ByHeart — including recalls across 60+ countries, hospitalizations, and unfortunately some infant deaths tied to contaminated ingredients like ARA oil and botulism spores. While Harmony isn't named in these incidents, the broader industry is clearly facing scrutiny around supply chain complexity and ingredient sourcing as formulas become more nutritionally sophisticated. How is Harmony approaching supply chain safety and ingredient sourcing for Melodi and your future Gen 2 products? What quality control and testing protocols do you have in place, particularly for bioactive compounds? Does the precision fermentation approach for Gen 2 reduce or increase supply chain risk compared to traditional ingredient sourcing? 2. Market Differentiation The hypoallergenic formula market is large, but established players (Abbott, Nestlé, Danone) already offer specialized products. What is truly unique about Harmony's formulas relative to existing hypoallergenic products on the market? Is the primary advantage taste, digestibility, allergen profile, biological similarity to human milk, or something else? For Melodi (toddler formula) specifically, what is its clear competitive edge? 3. Regulatory Path & Cash Runway Your Gen 2 precision fermentation-based formulas will presumably require lengthy regulatory approval processes. What is your expected regulatory timeline in Brazil vs. the US for Gen 2? Will cash generated from Melodi sales be sufficient to bridge you to Gen 2 approvals, or will additional fundraising be required? How does launching in Brazil first shape your go-to-market strategy for the US and Europe? 4. Geopolitical & Operational Risk With R&D operations and government funding based in Brazil: How do tariffs, trade regulations, and supply chain constraints affect your manufacturing costs? What are the logistics and regulatory hurdles for exporting to major markets like the US and Europe? Does the $5.9M Brazilian government grant come with any restrictions on where you can manufacture or sell? Thank you for your time. We look forward to your responses. — Sherwood Neiss, Managing Partner, D3VC
- Q: Hi Wendel, First Of All Happy New and wishing all the Best at Harmony. I am trying to contact you to support on all nutrients Supply. How can I contact you directly? Thanks and Kind Regards. Leon Reis
  - A: Hi Leon, you can contact care@harmonybabynutrition.com
- Q: Hi @Freeman, Great to hear from you! Manufacturing starts next month, and we’re on track to launch sales by the end of Q1 2026.This fundraising round is dedicated to securing manufacturing costs and accelerating commercial efforts, including strategic team expansion. We’re fully committed to executing this plan and confident in the milestones ahead.
- Q: Hello, congrats on your success to date and great problem you are trying to solve. Business question - when do you expect sales to start?
  - A: Hi @Freeman, Great to hear from you! Manufacturing starts next month, and we’re on track to launch sales by the end of Q1 2026.This fundraising round is dedicated to securing manufacturing costs and accelerating commercial efforts, including strategic team expansion. We’re fully committed to executing this plan and confident in the milestones ahead.
- Q: What is the share price
  - A: Hi Himansu, thank you for your questions. There is no fixed share price for this round. We’re raising on a SAFE with a $35M post-money valuation cap. Shares will convert at the next priced round based on that cap (or a 20% discount, if applicable).
- Q: Hi Wendel, Great approach to making life better. We're a vegan crowdfunding club. Are any animal products used or tested? Thanks.
  - A: Hi Mark,Great to hear from you and the Vegan Crowdfunding Club.Unfortunately, at this stage, there aren’t enough vegan ingredients— including human milk proteins produced via precision fermentation — that have been approved by regulatory authorities to enable a fully vegan infant nutrition product.That said, as we move from our Gen 1 through Gen 3 products, we are progressively replacing cow’s‑milk–based ingredients with human milk components. Our goal is to eliminate cow’s milk elements that are not found in human milk, using innovation and a strong scientific approach.Your support is an important step in this journey. I’d be happy to jump on a call to go into more detail and answer any questions.You can book time directly using my Calendly link: https://calendly.com/harmonybabynutrition/30minLooking forward to connecting.Best,Del
- Q: There is no doubt about it, folks, Del is the "Dean Of Disruption" in the baby milk industry!! It was great hearing your pitch yesterday and interacting with you at the KingsCrowd Investor Conference. I will definitely be investing in Harmony soon. Thank you for your wonderful work, Del!!
  - A: Tom, thank you so much for the incredibly kind words. It was a pleasure meeting you at the KingsCrowd Investor Conference.Your support and enthusiasm truly mean a lot to our team. We’re building Harmony with the goal of thoughtfully and responsibly redefining infant nutrition, and having investors like you alongside us makes this journey even more meaningful.Warm regards, Del Founder & CEO Harmony Baby Nutrition
- Q: amazing! I invested in several companies centered around babies, therefore, this is very intriguing. I am a vc and invest on sites like this. you are very smart to open a community round. congrats on what you have accomplished so far. few questions 1. with that being said I noticed you don't have an affiliate, ambassador program etc. would be very beneficial to have. I see one baby formula company is doing 15% commission for their affiliate program. 2. "Melodi is designed for toddlers with cow’s milk protein allergy (CMPA) or sensitivities who need a hypoallergenic formula" correct me if I am wrong but you plan on adding a product that way all babies can use it right? 3. obviously you aren't the only baby nutrition company how does your prices compare to others? 4. what is the distribution plan? 5. what is your moat? thanks for your time!
  - A: Hi John Great to hear from you! Thank you for your support! Please find the answers below: 1. Ambassador program We are developing an Advocacy Ecosystem targeting 'Allergy-Influencer' parents and community leaders. Harmony’s technical differentiation defined by a nutritional profile mirroring human milk, superior palatability, and a clean label provides a powerful, science-backed narrative for digital communicators seeking to solve the 'allergy gap' for their audiences.” Additionally, our healthy margins allow us to offer competitive commissions and incentives to our partners. 2. Strategic Phasing: Toddler-to-Infant Our immediate GTM focuses on the Toddler Drink category (12+ months). This allows us to commercialize our innovation immediately, generating revenue and real-world evidence while showcasing our scientific efficacy. This phase serves as a commercial runway to fund the longitudinal safety studies required for Infant Formula (0-12 months) regulatory approval within the next 24–36 months. 3. Pricing strategy Our supply chain and COGS provide a significant competitive hedge, even to go below the retail price of legacy leaders ($42–$45/can). However, Harmony is positioned to test different price strategies in different geographies and even considering 20-25% price premium, reflecting a high consumer "willingness to pay" for specialized, allergy-safe nutrition. This provides us with a strong customer acquisition capability compared to incumbents. 4. Distribution plans Harmony will launch its hypoallergenic toddler formula in the United States through a direct-to-consumer model. Sales will be conducted through our own e-commerce platform and fulfilled by a U.S.-based third-party logistics partner. This approach allows us to control brand positioning, manage inventory carefully during initial production, and build direct relationships with families. We plan to offer a subscription option to support recurring revenue and improve demand forecasting. Marketing will focus on digital channels, parent communities, and educational content tailored to caregivers managing food allergies and sensitivities. We will also engage healthcare professionals through educational outreach and sampling programs to support awareness, without relying on paid endorsements. Once we validate product-market fit and operational stability, we plan to expand into additional channels such as online marketplaces and select specialty retailers. Expansion will be milestone-based to ensure supply reliability and disciplined capital deployment. 5. Moat Our moat is built on three layers: Intellectual Property & R&D: A robust IP strategy protecting our formulation, combined with decades of specialized experience in developing ultra-complex nutritional profiles. Regulatory: A proven ability to navigate the increasingly stringent FDA/EFSA pathways for ingredients and formulas, a barrier to entry that deters smaller startups. The Emotional Lock-In: We don’t just sell units; we provide the "Milk Ladder" transition. By providing a risk-free path for allergic infants to wean off medical formulas, we create a high-retention "Peace of Mind" relationship that massive, generic brands cannot replicate.
- Q: How much of the Brazilian grant has been drawn? How much is left to draw?
  - A: Hi Justin, it has not been drawn yet. We are currently working within the government agency’s timeline, and the first tranche is expected to become available in Q3.
- Q: Team, 1). Are there any additional regulatory approvals you expect to require in the future? 2). Given that you already have several venture capital firms on your cap table and recently received a grant, why pursue a community round instead of raising capital from existing investors?
  - A: Hi Kunal, great to hear from you! Please find my answers below: 1. We have a full pipeline of infant nutrition products. Our Generation 1 products are already cleared and on their way to market. Products in Generations 2 and 3, which include a full complement of human milk components, will require additional regulatory steps and approvals before launch. Please keep in mind that Gen 1 products serve as the key foundation for building the most sophisticated and humanized infant nutrition solutions in our portfolio. Additionally, we have assembled a highly experienced regulatory team, including Nestlé’s former Global Head of Regulatory Affairs. 2. The main reason for a community round is that we’re building a strong community of supporters to help launch the product. This includes healthcare professionals, influencers, and parents who are not only closely following Harmony but are also eagerly awaiting the innovative solution we’re bringing to market. Many of them have firsthand experience with traditional infant nutrition products and are passionate about transforming this industry. Additionally, grants cannot be used for commercial purposes, which makes this round important for our go-to-market strategy. It will also complement the follow-on investments from our existing investors, including ReThink Foods and SAFAR Partners, Harmony’s largest backers. I’d be happy to schedule a call to clarify any questions and walk you through the work we’re doing. I’m confident you’ll find it very compelling and impactful. Best regards, Del Founder & CEO